Vendor comparison · 2026
Sermorelin vendors: 22 compared on COAs and price
Tissue & recoveryAlso known as GHRH (1-29), GRF 1-29
Evidence tier
Multiple human trials
3 human trials · 1 observational
- Vendors carrying it
- 22
- 21 with a listed price
- Vendors with checkable COAs
- 9
- 10 publish any certificate
- Lots tested
- 12
- 11 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 3 Sept 2026
- oldest 12 Dec 2025
- Laboratories named
- 7
- most often Freedom Diagnostics Testing
- Median label gap
- 5.5%
- 50% of lots within 5% of label
- Median purity
- 99.59%
- 11 of 12 lots at 99% or above
- Lowest price per mg
- $4.50
- peer median $7.20
- Publications located
- 331
- researched since 1984
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable Sermorelin testing in this index: 3 lots assayed by ILS Laboratories, the newest on 14 Aug 2026. The lowest listed price is $4.50 per mg at Next Gen Peptides, the same vendor, against a peer median of $7.20. 22 vendors carrying Sermorelin are compared below. 9 publish at least one certificate naming a checkable laboratory, 12 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Sermorelin
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $4.50 (63%) | 3 / 3 | ILS Laboratories | 99.7% | 4.8% | ||
| 2 | Ascend ScienceISO/IEC 17025 | 92.594% | $5.00 (69%) | 1 / 1 | Kovera Labs and/or ILS Labs | 99.7% | 3.0% | ||
| 3 | PeptidePlugs | 8994% | $5.50 (76%) | 1 / 1 | Freedom Diagnostics Testing | 99.1% | 11.0% | ||
| 4 | Amino ClubISO/IEC 17025Age-gated COAs | 88.898% | $6.00 (83%) | 0 | — | — | — | — | |
| 5 | Bench Grade Peptides | 86.589% | $5.10 (71%) | 1 / 1 | AV Analytics | 99.8% | 0.9% | ||
| 6 | Hydro Research PeptidesISO/IEC 17025 | 83.989% | — | 0 / 1 | Not named | 99.8% | 7.8% | ||
| 7 | Ascension Peptides | 81.489% | $7.20 (100%) | 1 / 1 | MZ Biolabs | 99.8% | 13.1% | ||
| 8 | Modern AminosISO/IEC 17025COAs need an account | 80.397% | $7.40 (103%) | 0 | — | — | — | — | no reportVisit site |
| 9 | Simple Peptide | 77.292% | $7.90 (110%) | 1 / 1 | Freedom Diagnostics Testing | 99.1% | 3.1% | ||
| 10 | Prime PeptidesISO/IEC 17025 | 76.396% | $7.00 (97%) | 0 | — | — | — | — | no reportVisit site |
| 11 | Northline LabsISO/IEC 17025 | 73.795% | $10.00 (139%) | 1 / 1 | Horizon Analytical | 99.2% | 16.0% | ||
| 12 | Good Science Bio | 70.871% | $6.00 (83%) | 0 | — | — | — | — | no reportVisit site |
| 13 | Protide HealthAge-gated COAs | 68.992% | $10.50 (146%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Koi PeptidesAge-gated COAs | 68.692% | $10.00 (139%) | 1 / 1 | Freedom Diagnostics Testing | 99.4% | 10.2% | ||
| 15 | Eternal Peptides | 65.863% | $5.85 (81%) | 0 | — | — | — | — | no reportVisit site |
| 16 | True Research Labs | 64.868% | $6.90 (96%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Evolve Peptides | 64.668% | $7.50 (104%) | 0 | — | — | — | — | no reportVisit site |
| 18 | GenX Peptides | 61.969% | $8.60 (119%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Licensed Peptides | 61.787% | $11.50 (160%) | 1 / 1 | Vanguard Laboratory | 98.4% | 5.0% | ||
| 20 | Mile High Compounds | 61.191% | $7.00 (97%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Biotech Peptides | 58.260% | $8.60 (119%) | 0 | — | — | — | — | no reportVisit site |
| 22 | Sports Technology LabsAge-gated COAs | 54.871% | $10.40 (144%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Sermorelin is on file. All 12 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
11 of 12 lots at 99% or above; median 99.59%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 1 |
| 99–99.5% | 4 |
| ≥99.5% | 7 |
50% of lots within 5% of the labelled mass; median gap 5.5%.
| Range | lots |
|---|---|
| ≤2% | 1 |
| 2–5% | 4 |
| 5–10% | 3 |
| 10–20% | 4 |
| >20% | 0 |
21 vendors, $4.50 to $11.50; median $7.20.
| Range | vendors |
|---|---|
| $4.00–$6.00 | 5 |
| $6.00–$8.00 | 9 |
| $8.00–$10.00 | 2 |
| $10.00–$12.00 | 5 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 3 | 3 | 25% | Public lookup |
| ILS LaboratoriesUS | 3 | 1 | 25% | Public lookup |
| AV Analytics | 1 | 1 | 8% | No public lookup found |
| Horizon Analytical | 1 | 1 | 8% | No public lookup found |
| Kovera Labs and/or ILS Labs | 1 | 1 | 8% | No public lookup found |
| MZ BiolabsUS | 1 | 1 | 8% | No public lookup found |
| Vanguard LaboratoryUS | 1 | 1 | 8% | No public lookup found |
1 further record namesno checkable laboratory (a placeholder, a signature line or the vendor’s own name). It is listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1984 — 42 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
331 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.4% across 12 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.42 pts purity across lots, mean label deviation 7.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
22 of 22 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
11 of 12 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Sermorelin?
A synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone, which stimulates the pituitary gland to release growth hormone.
Studied in published research for growth-hormone release, recovery and body composition.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Previously approved as a diagnostic agent and studied in human trials of growth-hormone secretion. PepIndex does not evaluate clinical significance and does not describe administration.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? — Clinical interventions in aging (2006)
Peer-reviewed article indexed in PubMed, published in Clinical interventions in aging (2006).
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) (2026)
Peer-reviewed article indexed in PubMed, published in Sports medicine (Auckland, N.Z.) (2026).
- Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug testing and analysis (2021)
Peer-reviewed article indexed in PubMed, published in Drug testing and analysis (2021).
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (1999)
Peer-reviewed article indexed in PubMed, published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (1999).
- A potentially effective drug for patients with recurrent glioma: sermorelin — Annals of translational medicine (2021)
Peer-reviewed article indexed in PubMed, published in Annals of translational medicine (2021).
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Translational andrology and urology (2020)
Peer-reviewed article indexed in PubMed, published in Translational andrology and urology (2020).
- In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides — Biomedical chromatography : BMC (2023)
Peer-reviewed article indexed in PubMed, published in Biomedical chromatography : BMC (2023).
Indexed studies4 human-evidence of 4
- Quantitative growth hormone secretion and final adult height — Human — controlled trial, 1999
The relationship of quantitative GH secretion to height, growth velocity and puberty is complex and has been the subject of extensive study in children. This study was designed to relate quantitative GH secretion to final height. Twenty tall (> 183 cm, 90th centile for adult height) and 20 short (< 166 cm, 10th centile) postpubertal men who had recently completed linear growth (age range 18-27 years). GH dynamics were studied on four occasions; insulin (0.15 units/kg, iv)-ind…
- Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report — Case report, 2026
Anterior cervical osteophytes can compress the esophagus, producing dysphagia. Although common on imaging in older adults, symptomatic osteophytic dysphagia is underdiagnosed, and the role of systemic anabolic factors in osteophyte growth is poorly characterized. A 62-year-old male ex-military recreational bodybuilder presented with cervicalgia and left shoulder pain. Cervical radiographs and MRI demonstrated multilevel degenerative changes including a prominent anterior oste…
- Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone — Human — controlled trial, 1993
To assess the growth-promoting effect of different doses of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in GH deficiency (GHD) of hypothalamic origin, 43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16). The LD group received GHRH(1-29)-NH2 at 30 micrograms/kg/day s.c…
- Growth hormone release by the novel GH releasing peptide hexarelin in patients with homozygous beta-thalassemia — Human — controlled trial, 1997
Patients with beta-thalassemia often present with abnormalities in growth and other endocrine functions. Growth hormone (GH) secretion is controlled via somatostatin and growth hormone releasing hormone (GHRH). Recently, Hexarelin, a new potent GH secretagogue (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), was synthesized. Our study was designed to assess and compare its efficacy as a GH secretagogue to GHRH 1-29 in beta-thalassemia. Eighteen patients, regularly transfused and c…
Evidence digest
What the research on Sermorelin actually shows
The indexed literature on Sermorelin includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Sermorelin is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.